glp 1 moa GLP-1 Agonists - What is it? GLP-1 Receptor Agonists – Peripheral

There is a risk of weight regain if the medication is discontinued

The glucometabolic effects of GLP-1 have been reviewed extensively elsewhere [18] and are not the focus of the current review

Poor nutrition and obesity disproportionately affect individuals with lower socioeconomic status in rural communities and in racial and ethnic minoritized populations [226], and disparities in poor nutrition and obesity prevalence are mirrored in disparities in access to quality health care [227]

This medications safety profile has not been studied in patients under the age of 18, pregnant and lactating people, or those with normal BMIs. At the time of publishing, the FDA has only approved three GLP-1 agonists for weight loss: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)

However, this offer only applies to vials of the drug, not the autoinjector pens